Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes

References

• American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011;34:S11–61.
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts M, Colwell J, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694–701.
   PubMed Web of Science ®Google Scholar
• Sirois C, Poirier P, Moisan J, Grégoire J-P. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?Int J Cardiol. 2008; 129:172–9.
   PubMed Web of Science ®Google Scholar
• Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007;28:1925–7.
   PubMed Web of Science ®Google Scholar
• Pignone M, Williams C. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol. 2010; 6:619–28.
   PubMed Web of Science ®Google Scholar
• Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87:211–18.
   PubMed Web of Science ®Google Scholar
• Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2011;10:25.
   PubMed Web of Science ®Google Scholar
• Stavakis S, Stoner J, Azar M, Wayangankar S, Thadani U. Low dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011;341:1–9.
   PubMed Web of Science ®Google Scholar
• Millar WJ, Young TK. Tracking diabetes: prevalence, incidence and risk factors. Health Rep. 2003;14:35–47.
   PubMedGoogle Scholar
• Ouhoummane N, Abdous B, Louchini R, Rochette L, Poirier P. Trends in postacute myocardial infarction management and mortality in patients with diabetes. A population-based study from 1995 to 2001. Can J Cardiol. 2010;26:523–31.
   PubMedGoogle Scholar
• Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008;28:s25–32.
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353:2373–83.
   PubMed Web of Science ®Google Scholar
• Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol. 1995;48:999–1009.
   PubMed Web of Science ®Google Scholar
• Levy AR, Tamblyn RM, Fitchett D, McLeod P, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999;15:1277–82.
   PubMed Web of Science ®Google Scholar
• Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148:99–104.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154: 854–64.
   PubMed Web of Science ®Google Scholar
• Belsley D, Kuh E, Welsch R. Regression diagnostics: identifying influential data and sources of collinearity. New York: Wiley; 1980.
   Google Scholar
• , Antithrombotic Trialists’ (ATT) CollaborationBaigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–35.
   PubMed Web of Science ®Google Scholar
• Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26:3264–72.
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41.
   PubMed Web of Science ®Google Scholar
• Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10:1220–30.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001; 52:563–71.
   PubMed Web of Science ®Google Scholar
• De Berardis G, Lucisano G, D’Ettore A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307;2286–94.
   PubMed Web of Science ®Google Scholar
• Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47:731–7.
   PubMed Web of Science ®Google Scholar
• Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol. 2008;103:872–82.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006;174:169–74.
   PubMed Web of Science ®Google Scholar
• Guénette L, Sirois C. Pharmacy record registration of acetyl salicylic acid (ASA) prescriptions in Quebec. J Pharm Pharmaceut Sci. 2012; 15:252–5.
   PubMed Web of Science ®Google Scholar